We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 61.00 | 3.29% | 1,915.00 | 1,914.00 | 1,916.00 | 1,918.00 | 1,861.00 | 1,861.00 | 174,135 | 14:59:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.98 | 4.22B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 4600O
Hikma Pharmaceuticals Plc
17 May 2018
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 17 May 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee has made the following conditional awards and nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 16 May 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Mazen Darwazah
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Mazen Darwazah
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Vice Chairman
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 16,953
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Mazen Darwazah
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Mazen Darwazah
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Vice Chairman
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 12,042
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Bassam Kanaan
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Bassam Kanaan
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Strategy and Corporate Development
Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 25,729
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Bassam Kanaan
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Bassam Kanaan
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Strategy and Corporate Development
Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 25,729
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Khalid Nabilsi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 23,062
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Khalid Nabilsi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 23,062
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Riad Mishlawi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Riad Mishlawi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status CEO, Injectables Division
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 22,601
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Riad Mishlawi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Riad Mishlawi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status CEO, Injectables Division
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 22,601
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Majda Labadi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Majda Labadi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Human Capital Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 15,855
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Majda Labadi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Majda Labadi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Human Capital Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 15,855
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Susan Ringdal
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Susan Ringdal
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy
and Investor Relations
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 14,257
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Susan Ringdal
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Susan Ringdal
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy
and Investor Relations
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 14,257
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Brian Hoffman
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Brian Hoffmann
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status President, US Generics Division
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 18,247
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Bryan Hotston
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Bryan Hotston
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Information Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 17,016
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Hussein Arkhagha
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Hussein Arkhagha
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status General Counsel
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP10.35
volume(s) Volume(s): 13,489
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 16 May 2018
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBDGDUDBBBGIR
(END) Dow Jones Newswires
May 17, 2018 08:45 ET (12:45 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
